An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder

Sriram Ramaswamy, Jayakrishna Madabushi, John Hunziker, Subhash Bhatia, Frederick Petty

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P

Original languageEnglish
Article number934162
JournalJournal of Aging Research
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Memantine
Post-Traumatic Stress Disorders
Veterans
Repression (Psychology)
Wechsler Scales
Memory Disorders
N-Methylaspartate
Short-Term Memory
Cognition
Language
Anxiety
Quality of Life
Outcome Assessment (Health Care)
Depression
Safety
Cognitive Dysfunction

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Cite this

An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder. / Ramaswamy, Sriram; Madabushi, Jayakrishna; Hunziker, John; Bhatia, Subhash; Petty, Frederick.

In: Journal of Aging Research, Vol. 2015, 934162, 2015.

Research output: Contribution to journalArticle

@article{03f7b936295043e1bb0068ec2ead5746,
title = "An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder",
abstract = "Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P",
author = "Sriram Ramaswamy and Jayakrishna Madabushi and John Hunziker and Subhash Bhatia and Frederick Petty",
year = "2015",
doi = "10.1155/2015/934162",
language = "English",
volume = "2015",
journal = "Journal of Aging Research",
issn = "2090-2204",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder

AU - Ramaswamy, Sriram

AU - Madabushi, Jayakrishna

AU - Hunziker, John

AU - Bhatia, Subhash

AU - Petty, Frederick

PY - 2015

Y1 - 2015

N2 - Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P

AB - Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P

UR - http://www.scopus.com/inward/record.url?scp=84930629871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930629871&partnerID=8YFLogxK

U2 - 10.1155/2015/934162

DO - 10.1155/2015/934162

M3 - Article

VL - 2015

JO - Journal of Aging Research

JF - Journal of Aging Research

SN - 2090-2204

M1 - 934162

ER -